WSE:INM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

InventionMed S.A. focuses on the development of medical simulators based on VR technology for use in education in esthetic and clinical dermatology.


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has InventionMed's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: INM's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.4%

INM

1.4%

PL Medical Equipment

4.4%

PL Market


1 Year Return

0%

INM

95.8%

PL Medical Equipment

-18.9%

PL Market

Return vs Industry: INM underperformed the Polish Medical Equipment industry which returned 93.5% over the past year.

Return vs Market: INM exceeded the Polish Market which returned -18.7% over the past year.


Shareholder returns

INMIndustryMarket
7 Day-13.4%1.4%4.4%
30 Day35.0%-12.0%7.2%
90 Day20.9%32.9%-3.1%
1 Year0%0%95.8%95.8%-17.0%-18.9%
3 Year223.5%223.5%-61.0%-61.5%-22.1%-27.5%
5 Year130.0%57.1%-57.4%-59.8%-19.6%-29.4%

Price Volatility Vs. Market

How volatile is InventionMed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is InventionMed undervalued compared to its fair value and its price relative to the market?

5.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate INM's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate INM's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: INM is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: INM is unprofitable, so we can't compare its PE Ratio to the Polish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate INM's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: INM is overvalued based on its PB Ratio (6x) compared to the PL Medical Equipment industry average (3x).


Next Steps

Future Growth

How is InventionMed forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as InventionMed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has InventionMed performed over the past 5 years?

47.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: INM is currently unprofitable.

Growing Profit Margin: INM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: INM is unprofitable, but has reduced losses over the past 5 years at a rate of 47% per year.

Accelerating Growth: Unable to compare INM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: INM is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-1.7%).


Return on Equity

High ROE: INM has a negative Return on Equity (-5.82%), as it is currently unprofitable.


Next Steps

Financial Health

How is InventionMed's financial position?


Financial Position Analysis

Short Term Liabilities: INM's short term assets (PLN146.8K) do not cover its short term liabilities (PLN354.2K).

Long Term Liabilities: INM's short term assets (PLN146.8K) exceed its long term liabilities (PLN1.4K).


Debt to Equity History and Analysis

Debt Level: INM is debt free.

Reducing Debt: INM has no debt compared to 5 years ago when its debt to equity ratio was 21.6%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: INM has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: INM has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 5.6% each year.


Next Steps

Dividend

What is InventionMed's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate INM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate INM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if INM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if INM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of INM's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Tomasz Kierul

no data

Tenure

Mr. Tomasz Kierul serves as the Chief Executive Officer and President of Management Board at Inventionmed SA. 


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

InventionMed S.A.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: InventionMed S.A.
  • Ticker: INM
  • Exchange: WSE
  • Founded: 2009
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: zł78.533m
  • Shares outstanding: 35.70m
  • Website: https://inventionmed.com

Location

  • InventionMed S.A.
  • ul. Bydgoskich Przemyslowców 6
  • Bydgoszcz
  • 85-862
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INMWSE (Warsaw Stock Exchange)YesCommon Bearer SharesPLPLNMar 2013

Biography

InventionMed S.A. focuses on the development of medical simulators based on VR technology for use in education in esthetic and clinical dermatology. Its flagship project is TutorDerm, a simulator and an application that lets users perform essential procedures needed for the treatment of specific skin aliments. InventionMed S.A. was founded in 2009 and is based in Bydgoszcz, Poland.  


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/28 20:18
End of Day Share Price2020/05/28 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.